

# Key Information Document for HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF (the Fund), a sub-fund of HANetf ICAV Class - Accumulating

## Purpose

This document provides you with key information about this investment Fund. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this Fund and to help you compare it with other Funds.

<b>Product</b>	HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF
<b>PRIP Manufacturer</b>	HANetf Management Limited
<b>ISIN</b>	IE00BJQTJ848
<b>Website</b>	<a href="http://www.hanetf.com">www.hanetf.com</a>
<b>Contacting the manufacturer</b>	Email: <a href="mailto:info@hanetf.com">info@hanetf.com</a> Tel +44 (0)203 794 1800
<b>Competent authority</b>	Central Bank of Ireland (the <b>Central Bank</b> ) is responsible for supervising HANetf Management Limited in relation to this Key Information Document
<b>Management Company</b>	HANetf Management Limited is authorised in Ireland and regulated by the Central Bank.
<b>KID Production Date</b>	12.06.2023

## What is this Fund?

<b>Type</b>	<p>The Fund is a sub-fund of HANetf ICAV (the <b>ICAV</b>), an open-ended Irish collective asset-management vehicle umbrella fund with segregated liability between sub-funds, with variable capital established under the laws of Ireland and authorised by the Central Bank under the UCITS Regulation 2011, as amended.</p> <p>The Fund seeks to track the price and yield performance, before fees and expenses, of the <b>Solactive Cloud</b> The Fund seeks to track the price and yield performance, before fees and expenses, of the Indxx Global NextGen Healthcare Index (the "<b>Index</b>"). The Index is governed by a published, rules-based methodology and is designed to measure the performance of an investable universe of global companies that are active in the Advanced Life Sciences &amp; Smart Healthcare sector and comprised of the following sub-themes: Robotics, Nanotechnology, Genome Sequencing, Healthcare Trackers, Biological Engineering, Bioinformatics, Neuroscience, Medical Devices, Telemedicine and Healthcare Analytics.</p> <p>To be eligible for inclusion in the Index, companies must:</p> <ul style="list-style-type: none"> <li>• have their primary listing in "Developed and Emerging Markets" as defined by the Index administrator in its "Country Classification and Inevitability" document;</li> <li>• derive a majority of their assets or revenues from global companies that are active in the Advanced Life Sciences &amp; Smart Healthcare sector and comprised of the following sub-themes: Robotics, Nanotechnology, Genome Sequencing, Healthcare Trackers, Biological Engineering, Bioinformatics, Neuroscience, Medical Devices, Telemedicine and Healthcare Analytics;</li> <li>• meet the minimum market capitalisation and liquidity requirements; and</li> <li>• must not be excluded based on the negative ESG screening and violations of UN Global Compact principles criteria as set out in the Supplement.</li> </ul> <p>The Index constituents are equally weighted The Index is reconstituted and rebalanced on a semi-annual basis in June and December based on the above eligibility criteria at which time the securities are equally weighted. The Fund employs a "passive management" (or indexing) investment approach and will seek to employ a replication methodology, meaning insofar as possible and practicable, it will invest in the securities comprising the Index.</p>
<b>Objectives and Policies</b>	
<b>Depository</b>	J.P. Morgan SE - Dublin Branch (the <b>Depository</b> )
<b>Additional Information</b>	<p>Shares of the Fund are listed on one or more stock exchanges. Typically, only authorised participants (i.e., brokers) can purchase Shares from or sell Shares back to the Fund. Other investors can purchase and sell shares on exchange on each day the relevant stock exchange is open.</p> <p>Income received by the Fund's investments will not be distributed in respect of the shares of this class. Instead, it will be accumulated and reinvested on behalf of the shareholders of the Fund.</p> <p>Further information such as fund prospectus, latest annual report and latest NAV can be obtained free of charge under <a href="http://www.hanetf.com">www.hanetf.com</a></p>
<b>Term</b>	The fund has no minimum fixed term, although the recommended holding period is 5 years. Termination of the Fund is only possible in those cases expressly provided for in the Prospectus or Supplement of the Fund.
<b>Intended retail investor</b>	The Fund is intended to be offered to retail investors who are seeking capital growth over the long term. An investment should only be made by those persons who are able to sustain a loss on their investment. Typical investors in the Fund are expected to be investors who want to take exposure to the markets covered by the Fund's investment policy and are prepared to accept the risks associated with an investment of this type, including the volatility of such market.

## What are the risks and what could I get in return?

### Summary Risk Indicator



The risk indicator assumes you keep the Fund for 5 years.  
The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this Fund compared to other Funds. It shows how likely it is that the Fund will lose money because of movements in the markets or because we are not able to pay you. We have classified this Fund as 5 out of 7, which is a high-risk class.

This classification takes into consideration two elements:

1) the market risk - that rates the potential losses from future performance at a high level; and 2) the credit risk which estimates that poor market conditions are very unlikely to impact our capacity to pay you.

**Be aware of currency risk. The Fund invests in securities denominated in currencies other than its base currency. Changes in the exchange rates may adversely affect the performance of the Fund. This risk is not considered in the indicator shown above.**

The Fund does not include any protection from future market performance so you could lose some or all of your investment. Investment by the Fund in other collective investment schemes, emerging markets and use of derivatives may involve additional risks. Please refer to the "Risk Factors" sections of the Prospectus and the Fund's Supplement which are available at [www.hanetf.com](http://www.hanetf.com).

### Performance Scenarios

What you will get from this Fund depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted. The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the Fund over the next 5 years. The scenarios shown are illustrations based on results from the past and on certain assumptions.

Recommended holding period		5 years		
Scenarios		If you exit after 1 year	If you exit after 3 years	If you exit after 5 years (RHP)
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment			
Stress scenario	What you might get back after costs	1,590 USD	2,965 USD	1,937 USD
	Average return	-84.1%	-33.3%	-28.0%
Unfavourable scenario	What you might get back after costs	7,118 USD	5,351 USD	4,318 USD
	Average return	-28.8%	-18.8%	-15.5%
Moderate scenario	What you might get back after costs	9,725 USD	9,180 USD	8,666 USD
	Average return	-2.8%	-2.8%	-2.8%
Favourable scenario	What you might get back after costs	13,248 USD	15,704 USD	17,341 USD
	Average return	32.5%	16.2%	11.6%

The figures shown include all the costs of the Fund itself but may not include all the costs that you pay to your advisor or distributor/and includes the costs of your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back. Due to market risk exposure, you can lose some or all of the amount invested during the recommended holding period of 5 years.

- **The stress scenario** shows what you might get back in extreme market circumstances.
- **Unfavourable scenario:** This type of scenario occurred for an investment between 2017 and 2023.
- **Moderate scenario:** This type of scenario occurred for an investment between 2017 and 2023.
- **Favourable Scenario:** This type of scenario occurred for an investment between 2017 and 2023.

### What happens if the HANetf Management Limited is unable to pay out?

HANetf Management Limited, as PRIIPS manufacturer of the Fund, is not obliged to make any payment in relation to the Fund, such obligations being those of the Fund itself. The assets of the Fund are kept separately from those of the Manager. An insolvency or default of the Manager should not result in the Fund suffering any financial loss in relation to its assets. The amount the Fund is obliged to pay out is linked to the net assets of the Fund so it is unlikely that the Fund will be unable to pay out unless there is an operational error or an insolvency or default by the Depositary which holds the Fund's assets on its behalf. In the event of the insolvency or default of the Depositary, securities held by the depositary on behalf of the Fund should be protected but the Fund may suffer loss in relation to cash and certain other assets which are not protected. Investment in the Fund is not covered by any investor protection scheme."

### What are the Costs?

The party advising on or selling you this Fund may charge you other costs. If so, this party will provide you with information about these costs and how they affect your investment.

### Costs over time

The tables show the amounts that are taken from your investment to cover one-off, ongoing and incidental costs. These amounts depend on how much you invest, how long you hold the Fund and how well the Fund performs]. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year] you would get back the amount that you invested (0 % annual return).
- For the other holding periods we have assumed the Fund performs as shown in the moderate scenario.
- USD 10,000 is invested.

## Investment USD 10,000

Scenarios	If you exit after 1 year	If you exit after 3 years	If you exit after 5 years
Total costs	57.72 USD	164.42 USD	260.24 USD
Annual cost impact	0.59%	0.59%	0.59%

## Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	0 % of the amount you pay in when entering this investment	USD
Exit costs	0 % of your investment before it is paid out to you	USD
Ongoing costs		
Management fees and other administrative or operating costs	0.59% of the value of your investment per year". This is an estimate based on actual costs over the last year.	USD
Transaction costs	0.06% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the Fund. The actual amount will vary depending on how much we buy and sell.	USD
Incidental costs taken under specific conditions		
Performance fees	There is no performance fee for this Fund.	Nil

## How long should I hold the Fund and can I take my money out early?

The Fund has no required minimum holding period but is designed for longer-term investment, though it is recommended that you stay invested for at least 5 years. Investors are able to sell their investment on any day on which banks are open in the UK. When you cash in or if you switch between sub-funds, there may be a delay of up to 5 days for this Fund. By selling the Fund earlier than the recommended holding period, you may receive back less than you would have received if you had stayed invested until maturity. A redemption or exchange fee of up to 3% may be payable to the Manager in such circumstances, as well as any fees that may be charged by your broker.

You can make regular and one-off withdrawals. Withdrawals could be greater than any growth achieved and could reduce your investment's value below the amount invested. You should refer to the Prospectus and Supplement for this Fund for the conditions that apply and information on tax.

## How can I complain?

In the event you should wish to complain at any time about this Fund, or the service you have received, please contact the marketing agent, HANetf Limited.

Address: City Tower, 40 Basinghall St, London, EC2V 5DE

Email: [info@hanetf.com](mailto:info@hanetf.com).

Website: [www.hanetf.com](http://www.hanetf.com)

## Other relevant information

Further information about the ICAV and the Fund (including the Prospectus, the Fund's Supplement and most recent financial statements) are available at [www.hanetf.com](http://www.hanetf.com). Additional information in relation to the product's performance over the past year is available under [https://etp.hanetf.com/past\\_performance\\_priip](https://etp.hanetf.com/past_performance_priip).

The information contained in this Key Information Document does not constitute a recommendation to buy or sell the Fund and is no substitute for individual consultation with your bank or advisor. The Fund is not in any way sponsored, sold or promoted by any relevant stock market, relevant index, related exchange or index sponsor. Further information in respect of the index is available from the index administrator.

This document may be updated from time to time. The latest Key Information Document is available online at [www.hanetf.com](http://www.hanetf.com)

**FOR SWISS INVESTORS ONLY:** The Fund has appointed as Swiss Representative Waystone Fund Services (Switzerland) SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Tel: +41 21 311 17 77, email: [switzerland@waystone.com](mailto:switzerland@waystone.com). The Fund's Swiss paying agent is Helvetische Bank AG. The Prospectus, the Key Investor Information Documents, the Instrument of Incorporation as well as the annual and semi-annual reports may be obtained free of charge from the Swiss Representative in Lausanne. The issue and redemption prices are published at each issue and redemption on [www.fundinfo.com](http://www.fundinfo.com)